Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07547436 · ClinicalTrials.gov registry record · Phase 2
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
A Phase 2 study, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT07547436 is a Phase 2 study that is actively recruiting participants, run by Sanofi. The registered enrollment target is 70 participants.
The verdict
NCT07547436, a Phase 2 study, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL SAR445399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2028-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07547436
The ClinicalTrials.gov registry entry for NCT07547436 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07547436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07547436 about?
NCT07547436 is a clinical study titled "A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis". This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
What is the current status of trial NCT07547436?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2026-06-08. Estimated completion is 2028-08-07.
What interventions are being tested in trial NCT07547436?
The interventions under investigation include: Placebo (BIOLOGICAL), SAR445399 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07547436?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.